The user is exploring hair growth stimulants other than Minoxidil, mentioning Stemoxydine, various peptides, drugs like Latanoprost and Bimatoprost, and natural remedies such as Rosemary Oil and Caffeine. They express concerns about the long-term effectiveness and safety of these alternatives and seek more information on viable options for hair regrowth.
GT20026 is discussed as a potential treatment for hair loss that targets androgen receptors without affecting hormone levels, but it may not promote significant regrowth. It is expected to be available by 2028, with other treatments like Breezula and Clascoterone also mentioned.
A user switched from finasteride to Avodart (dutasteride) due to the ineffectiveness and poor quality of finasteride in their country. They advise others in similar situations to seek original brands.
Oral finasteride is recommended over topical finasteride for men in the Indian subcontinent, with no reported side effects. Minoxidil and dermarolling are also suggested, while dietary supplements and topical finasteride are deemed less effective.
The conversation humorously discusses hair loss treatments, including minoxidil and finasteride, with a satirical suggestion of using fence castration as a natural finasteride for male deer. Participants joke about the side effects and effectiveness of these treatments.
The user is considering switching from finasteride to dutasteride and possibly using oral minoxidil to address hair loss, having seen some progress with topical treatments and microneedling. They are also contemplating a hair transplant in the future and seeking advice on obtaining medications in Italy.
The conversation discusses experiences with Haircross Hair Growth Serum, which contains Redensyl, Capixyl, Procapil, Anagain, and Baicapil, as an alternative to Minoxidil and Finasteride. Users report mixed results, with some experiencing no regrowth and others noting slight thickening, but concerns about side effects and effectiveness compared to standard treatments remain.
A user (Majestic-Head3874) who has had successful hair regrowth with the combination of topical minoxidil, oral finasteride and microneedling treatments. People are asking for details about these treatments and Majestic-Head3874 is sharing the regimen they used.
Baldness is difficult to cure because current treatments like finasteride, dutasteride, and minoxidil only prevent hair shedding, and new developments are mostly ineffective. Botox shows potential in aiding skin regeneration and hair growth, but maintenance therapy with treatments like dutasteride and minoxidil may still be necessary.
The user stopped using topical finasteride and minoxidil, leading to hair thinning and shedding, and has since restarted the treatment. They are experiencing significant shedding and are seeking advice on whether this is normal and when improvement might occur, while using a regimen that includes Nutrafol, microneedling, Nioxin, and Nizoral.
Hope Medicine's announcement of the HMI-115 Phase II clinical trial for androgenetic alopecia in China; other related trials have been conducted or are ongoing in different countries, including Australia, US, and Europe. There is speculation that the product may be accepted across borders without additional testing.
The user started oral minoxidil, finasteride, and later switched to dutasteride, also using Nutrafol, dermastamp, and ketoconazole shampoo, but experienced increased thinning with little regrowth. Others advised patience, suggesting it takes 6-18 months to see results, and noted that initial thinning is normal when switching treatments.
A user is considering using RU58841 for female pattern baldness and is also planning to use Minoxidil. They are hesitant to ask their doctor for spironolactone due to its cosmetic nature and are experiencing significant hair loss possibly due to stress and hormonal issues.
New hair loss treatments like VDPHL01, PP405, Gt20029, and Breezula are anticipated, with VDPHL01 possibly releasing in 2027/28. Current treatments include finasteride, dutasteride, and minoxidil, but new options are eagerly awaited.
Dutasteride users have mixed results in hair loss treatment, with some experiencing improvements and others worsening. Some report metabolic changes like weight gain or diabetes, while others have no significant side effects.
The user has tried topical Minoxidil and oral Minoxidil for beard and scalp hair growth with minimal results, and has been on Finasteride for 7 months with stabilized scalp hair but no facial hair improvement. They are considering using a SULT1A1 enzyme booster to enhance results and are questioning its effectiveness without concurrent topical Minoxidil application.
Concerns about the long-term effects of dutasteride and finasteride on fertility, with discussions on cycling these medications to mitigate risks. The conversation highlights skepticism about study methodologies and the importance of weighing treatment risks against potential fertility issues.
A user is seeking a hair loss formula containing Redensyl and Capixyl without caffeine, Saw Palmetto, or other herbs. They want recommendations for such a product.
HMI-115 is a new drug developed by Bioinvent and licensed by Bayer, with mixed opinions on its potential effectiveness. Some users are skeptical and prefer proven treatments like Minoxidil, finasteride, and RU58841.
The conversation is about seeking updates on the hair loss treatment RCH-01, specifically its next phase and any news from Shiseido. The user recalls someone being in contact with a researcher or company representative.
A 19-year-old male has been using topical finasteride and minoxidil for 8 months with no progress and is considering seeking a second opinion due to potential misdiagnosis. The discussion revolves around whether the hair loss is due to male pattern baldness, alopecia areata, or a vitamin deficiency.
User reports 12-week progress with HIMS spray, Minoxidil, micro-needling, and biotin. Notable baby hairs on crown and temples, hoping for further improvement.
A 19-year-old has been using oral finasteride and minoxidil for a year without noticeable results. Suggestions include adding derma-stamping, increasing ketoconazole shampoo use, and considering vitamin D testing, while acknowledging that response times vary.
Cassiopea claimed that their hair loss treatment, Clascoterone, shows comparable results to finasteride after six months of use. Some users believe Clascoterone could be an additional treatment option for those who do not respond to finasteride.
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
The user is considering switching from topical Minoxidil to oral Minoxidil due to concerns about maintaining a topical routine. They have already started finasteride and are trying to prevent further hair loss progression.
A user struggled with hair loss and ineffective vitamin treatments from their doctor. They eventually obtained a finasteride prescription through a telemedicine service and felt relieved.